AtaiBeckley director Robert Hershberg sold 100,000 shares of common stock on July 7, 2026, generating $496,000 in gross proceeds at $4.96 per share. The transaction was executed automatically under a Rule 10b5-1 trading plan adopted on April 7, 2026, and involved the same-day exercise of vested stock options with a $1.35 strike price. Following the sale, Hershberg's direct common stock holdings were reduced by 50% to 100,000 shares, though he continues to hold 404,869 derivative securities. At the time of the sale, the company's shares had returned 89% over the prior one-year period. AtaiBeckley is a clinical-stage biopharmaceutical company with a market capitalization of $1.90 billion, minimal revenue, and a net loss of $663.4 million over the trailing twelve months.
ATAI Life Sciences BVDirector sold shares under a pre-set trading plan, which is routine and not indicative of negative outlook; the sale was part of a 10b5-1 plan.